Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals announced positive feedback from a Type C meeting with the U.S. FDA regarding their lead product candidate QRX003 for Netherton Syndrome. The FDA indicated that a single Phase 3 study may suffice for marketing approval in the U.S., offering flexibility on innovative trial designs without a traditional placebo control. Quoin pl…